First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 + Non-Hodgkin Lymphomas

• Published in: Clinical cancer research 2020-06, Vol.26 (11), p.2524-2534
• Main Authors: Gopal, Ajay K, Levy, Ronald, Houot, Roch, Patel, Sandip P, Popplewell, Leslie, Jacobson, Caron, Mu, Xinmeng J, Deng, Shibing, Ching, Keith A, Chen, Ying, Davis, Craig B, Huang, Bo, Fly, Kolette D, Thall, Aron, Woolfson, Adrian, Bartlett, Nancy L
• Format: Article
• Language: English
• Subjects: Life Sciences
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-19-2973

In this phase I study (NCT01307267), we evaluated safety, pharmacokinetics, clinical activity, and pharmacodynamics of treatment with utomilumab plus rituximab in patients with relapsed/refractory follicular lymphoma (FL) and other CD20 non-Hodgkin lymphomas (NHL). Primary objectives were to assess treatment safety and tolerability for estimating the MTD, using a modified time-to-event continual reassessment method, and selecting the recommended phase II dose (RP2D). Sixty-seven patients received utomilumab (0.03-10.0 mg/kg every 4 weeks) and rituximab (375 mg/m weekly) in the dose-escalation groups or utomilumab (1.2 mg/kg every 4 weeks) plus rituximab in the dose-expansion cohort. No patient experienced dose-limiting toxicity. The MTD for utomilumab in combination with rituximab was not reached and estimated to be ≥10 mg/kg every 4 weeks. The majority of the utomilumab treatment-related adverse events (AE) were grade 1 to 2; the most common AE was fatigue (16.4%). The pharmacokinetics of utomilumab in combination with rituximab was linear in the 0.03 to 10 mg/kg dose range. A low incidence (1.5%) of treatment-induced antidrug antibodies against utomilumab was observed. The objective response rate was 21.2% (95% CI, 12.1%-33.0%) in all patients with NHL, including four complete and 10 partial responses. Analysis of paired biopsies from a relapsed/refractory FL patient with complete response showed increased T-cell infiltration and cytotoxic activity in tumors. Biomarker correlations with outcomes suggested that clinical benefit may be contingent on patient immune function. Utomilumab in combination with rituximab demonstrated clinical activity and a favorable safety profile in patients with CD20 NHLs.